Literature DB >> 27837104

Cutting Edge: BAFF Overexpression Reduces Atherosclerosis via TACI-Dependent B Cell Activation.

Shaun W Jackson1,2, Nicole E Scharping1, Holly M Jacobs1, Shari Wang3, Alan Chait3, David J Rawlings4,2,5.   

Abstract

Patients with systemic lupus erythematosus exhibit accelerated atherosclerosis, a chronic inflammatory disease of the arterial wall. The impact of B cells in atherosclerosis is controversial, with both protective and pathogenic roles described. For example, natural IgM binding conserved oxidized lipid epitopes protect against atherosclerosis, whereas anti-oxidized low-density lipoprotein (oxLDL) IgG likely promotes disease. Because BAFF promotes B cell class-switch recombination and humoral autoimmunity, we hypothesized that excess BAFF would accelerate atherosclerosis. In contrast, BAFF overexpression markedly reduced hypercholesterolemia and atherosclerosis in hyperlipidemic mice. BAFF-mediated atheroprotection required B cells and was associated with increased protective anti-oxLDL IgM. Surprisingly, high-titer anti-oxLDL IgM production and reduced atherosclerosis was dependent on the BAFF family receptor transmembrane activator and CAML interactor. In summary, we identified a novel role for B cell-specific, BAFF-dependent transmembrane activator and CAML interactor signals in atherosclerosis pathogenesis, of particular relevance to the use of BAFF-targeted therapies in systemic lupus erythematosus.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27837104      PMCID: PMC5147509          DOI: 10.4049/jimmunol.1601198

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses.

Authors:  S Xu; K P Lam
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

3.  The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.

Authors:  Yasuhito Hamaguchi; Junji Uchida; Derek W Cain; Guglielmo M Venturi; Jonathan C Poe; Karen M Haas; Thomas F Tedder
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

4.  A role for BLyS in the activation of innate immune cells.

Authors:  Sook Kyung Chang; Bonnie K Arendt; Jaime R Darce; Xiaosheng Wu; Diane F Jelinek
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

5.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

6.  The inhibitory FcγRIIb modulates the inflammatory response and influences atherosclerosis in male apoE(-/-) mice.

Authors:  Yanice V Mendez-Fernandez; Bonnie G Stevenson; Cody J Diehl; Nicole A Braun; Nekeithia S Wade; Roman Covarrubias; Sander van Leuven; Joseph L Witztum; Amy S Major
Journal:  Atherosclerosis       Date:  2010-10-20       Impact factor: 5.162

7.  Risk factors for cardiovascular disease in systemic lupus erythematosus.

Authors:  E Svenungsson; K Jensen-Urstad; M Heimbürger; A Silveira; A Hamsten; U de Faire; J L Witztum; J Frostegård
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

8.  A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene.

Authors:  D Kitamura; J Roes; R Kühn; K Rajewsky
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

9.  Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development.

Authors:  Vassilia-Ismini Alexaki; George Notas; Vassiliki Pelekanou; Marilena Kampa; Maria Valkanou; Panayiotis Theodoropoulos; Efstathios N Stathopoulos; Andreas Tsapis; Elias Castanas
Journal:  J Immunol       Date:  2009-10-14       Impact factor: 5.422

10.  BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses.

Authors:  Qunrui Ye; Liqing Wang; Andrew D Wells; Ran Tao; Rongxiang Han; Anne Davidson; Martin L Scott; Wayne W Hancock
Journal:  Eur J Immunol       Date:  2004-10       Impact factor: 5.532

View more
  15 in total

Review 1.  B cells and atherosclerosis.

Authors:  Prasad Srikakulapu; Coleen A McNamara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-03-17       Impact factor: 4.733

Review 2.  BAFF inhibition in SLE-Is tolerance restored?

Authors:  Shaun W Jackson; Anne Davidson
Journal:  Immunol Rev       Date:  2019-09-28       Impact factor: 12.988

Review 3.  Cardiovascular disease in systemic lupus erythematosus.

Authors:  Maureen McMahon; Richard Seto; Brian J Skaggs
Journal:  Rheumatol Immunol Res       Date:  2021-12-15

4.  Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis.

Authors:  Corinna Schmitz; Heidi Noels; Omar El Bounkari; Eva Straussfeld; Remco T A Megens; Marieke Sternkopf; Setareh Alampour-Rajabi; Christine Krammer; Pathricia V Tilstam; Norbert Gerdes; Christina Bürger; Aphrodite Kapurniotu; Richard Bucala; Joachim Jankowski; Christian Weber; Jürgen Bernhagen
Journal:  FASEB J       Date:  2018-03-15       Impact factor: 5.191

Review 5.  Readapting the adaptive immune response - therapeutic strategies for atherosclerosis.

Authors:  Andrew P Sage; Ziad Mallat
Journal:  Br J Pharmacol       Date:  2017-02-01       Impact factor: 8.739

6.  A BAFF/APRIL axis regulates obesogenic diet-driven weight gain.

Authors:  Calvin C Chan; Isaac T W Harley; Paul T Pfluger; Aurelien Trompette; Traci E Stankiewicz; Jessica L Allen; Maria E Moreno-Fernandez; Michelle S M A Damen; Jarren R Oates; Pablo C Alarcon; Jessica R Doll; Matthew J Flick; Leah M Flick; Joan Sanchez-Gurmaches; Rajib Mukherjee; Rebekah Karns; Michael Helmrath; Thomas H Inge; Stuart P Weisberg; Sünje J Pamp; David A Relman; Randy J Seeley; Matthias H Tschöp; Christopher L Karp; Senad Divanovic
Journal:  Nat Commun       Date:  2021-05-18       Impact factor: 14.919

7.  Angiotensin II synergizes with BAFF to promote atheroprotective regulatory B cells.

Authors:  Padmapriya Ponnuswamy; Jeremie Joffre; Olivier Herbin; Bruno Esposito; Ludivine Laurans; Christoph J Binder; Thomas F Tedder; Lynda Zeboudj; Xavier Loyer; Andreas Giraud; Yujiao Zhang; Alain Tedgui; Ziad Mallat; Hafid Ait-Oufella
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

Review 8.  Beyond Macrophages and T Cells: B Cells and Immunoglobulins Determine the Fate of the Atherosclerotic Plaque.

Authors:  Harald Mangge; Florian Prüller; Wolfgang Schnedl; Wilfried Renner; Gunter Almer
Journal:  Int J Mol Sci       Date:  2020-06-08       Impact factor: 5.923

Review 9.  Anti-inflammatory and Immunomodulatory Therapies in Atherosclerosis.

Authors:  Justine Deroissart; Florentina Porsch; Thomas Koller; Christoph J Binder
Journal:  Handb Exp Pharmacol       Date:  2022

Review 10.  B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications.

Authors:  Tanyaporn Pattarabanjird; Cynthia Li; Coleen McNamara
Journal:  JACC Basic Transl Sci       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.